Sandoz loses another round in bid to market Biaxin XL generic
This article was originally published in Scrip
Executive Summary
A US appeals court has upheld a 2007 district court ruling that granted Abbott's motion for a preliminary injunction to stop Sandoz(Novartis) from selling a generic version of Biaxin XL (extended-release clarithromycin). Sandoz has thus lost its bid to resume marketing its generic version before a trial on a patent dispute over the product.